oral glp-1 drugs in development Timeline of discovery and clinical development. (a) Key events Oral GLP-1 Medication Helps Patients

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality

doi: 10.7759/cureus.66311

Rabizadeh S, Nakhjavani M, Esteghamati A (2019) Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review

Food and Drug Administration (FDA) in 2005 as a glucose-lowering treatment in T2DM [6]

So its actually twofold, the duties themselves plus the capital to put your infrastructure in place, which is obviously then you lose your ultra-low cost advantage and you You have to align more with the Amazon, or you abandon the market, which, and Im no expert there, but I would tend to think that this is not something they want to do